Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.

Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, Lacombe L, Guillemette C.

Br J Cancer. 2020 Feb 12. doi: 10.1038/s41416-020-0749-2. [Epub ahead of print]

PMID:
32047296
2.

Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.

Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Lévesque É, Klotz L, Guillemette C.

J Urol. 2019 Dec 17:101097JU0000000000000699. doi: 10.1097/JU.0000000000000699. [Epub ahead of print]

PMID:
31845837
3.

Best practices for enhancing surgical research: a perspective from the Canadian Association of Chairs of Surgical Research

Sener A, Anderson CC, Auger FA, Barralet J, Brindle M, Cayabyab FS, Fehlings MG, Lacombe L, Perrault LP, Sabbagh R, Seely AJ, Wallace C, Ellsmere J, Keijzer R.

Can J Surg. 2019 Dec 1;62(6):488-498. doi: 10.1503/cjs.012619.

4.

Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.

Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, Lévesque É, Guillemette C.

Drug Metab Dispos. 2020 Feb;48(2):75-84. doi: 10.1124/dmd.119.088229. Epub 2019 Nov 14.

PMID:
31727674
5.

Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?

McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P.

Clin Genitourin Cancer. 2019 Dec;17(6):e1122-e1128. doi: 10.1016/j.clgc.2019.07.016. Epub 2019 Aug 5.

PMID:
31594737
6.

Genome-wide germline correlates of the epigenetic landscape of prostate cancer.

Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi TN, Rouette A, Foucal A, Espiritu SMG, Sinha A, Sam M, Timms L, Johns J, Wong A, Murison A, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Lupien M, Fradet Y, Têtu B, McPherson JD, Pasaniuc B, Kislinger T, Chua MLK, Pomerantz MM, van der Kwast T, Freedman ML, Mani RS, He HH, Bristow RG, Boutros PC.

Nat Med. 2019 Oct;25(10):1615-1626. doi: 10.1038/s41591-019-0579-z. Epub 2019 Oct 7.

PMID:
31591588
7.

Exact Potential Energy Surface for Molecules in Cavities.

Lacombe L, Hoffmann NM, Maitra NT.

Phys Rev Lett. 2019 Aug 23;123(8):083201. doi: 10.1103/PhysRevLett.123.083201.

PMID:
31491208
8.

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.

Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, Lattouf JB, van der Kwast T, Trudel D, Mes-Masson AM, Saad F; Canadian Prostate Cancer Biomarker Network.

PLoS Med. 2019 Jul 2;16(7):e1002847. doi: 10.1371/journal.pmed.1002847. eCollection 2019 Jul.

9.

On the numerical solution of the exact factorization equations.

Gossel GH, Lacombe L, Maitra NT.

J Chem Phys. 2019 Apr 21;150(15):154112. doi: 10.1063/1.5090802.

PMID:
31005081
10.

Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series.

Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M.

Urol Oncol. 2019 May;37(5):300.e9-300.e15. doi: 10.1016/j.urolonc.2019.01.017. Epub 2019 Mar 12.

PMID:
30871997
11.

Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.

Émond JP, Labriet A, Desjardins S, Rouleau M, Villeneuve L, Hovington H, Brisson H, Lacombe L, Simonyan D, Caron P, Périgny M, Têtu B, Fallon JK, Klein K, Smith PC, Zanger UM, Guillemette C, Lévesque E.

Drug Metab Dispos. 2019 May;47(5):444-452. doi: 10.1124/dmd.119.086330. Epub 2019 Feb 28.

PMID:
30819787
12.

Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada.

Wissing MD, Chevalier S, O'Flaherty A, McKercher G, Aprikian S, Saad F, Carmel M, Lacombe L, Hamel M, Aprikian A.

Psychooncology. 2019 Apr;28(4):839-846. doi: 10.1002/pon.5031. Epub 2019 Feb 27.

PMID:
30762265
13.

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH.

Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.

14.

A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer.

Lévesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):701-706. doi: 10.1158/1055-9965.EPI-18-1002. Epub 2019 Feb 7.

PMID:
30733309
15.

Density-Matrix Coupled Time-Dependent Exchange-Correlation Functional Approximations.

Lacombe L, Maitra NT.

J Chem Theory Comput. 2019 Mar 12;15(3):1672-1678. doi: 10.1021/acs.jctc.8b01159. Epub 2019 Feb 14.

PMID:
30689380
16.

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F.

Endocr Connect. 2019 Feb;8(2):132-140. doi: 10.1530/EC-18-0476.

17.

Exploring non-adiabatic approximations to the exchange-correlation functional of TDDFT.

Fuks JI, Lacombe L, Nielsen SEB, Maitra NT.

Phys Chem Chem Phys. 2018 Nov 7;20(41):26145-26160. doi: 10.1039/c8cp03957g. Epub 2018 Oct 12.

PMID:
30311615
18.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

19.

The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer.

Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, O'Flaherty A, Scarlata E, Saad F, Carmel M, Lacombe L, Brimo F, Latour M, Ekindi-Ndongo N, Têtu B, Aprikian A.

World J Urol. 2019 May;37(5):789-798. doi: 10.1007/s00345-018-2457-6. Epub 2018 Aug 22.

PMID:
30136199
20.

Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.

Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Aprikian A.

BJU Int. 2019 Apr;123(4):624-631. doi: 10.1111/bju.14512. Epub 2018 Sep 11.

PMID:
30113732
21.

Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer.

Pelletier J, Cyr SJ, Julien AS, Fradet Y, Lacombe L, Toren P.

Urol Oncol. 2018 Aug;36(8):363.e7-363.e11. doi: 10.1016/j.urolonc.2018.05.004. Epub 2018 Jun 5.

PMID:
29880461
22.

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12.

23.

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.

Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI.

Pathol Oncol Res. 2019 Jul;25(3):979-986. doi: 10.1007/s12253-018-0408-6. Epub 2018 Apr 6.

PMID:
29623528
24.

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F.

Eur Urol Focus. 2019 Nov;5(6):998-1006. doi: 10.1016/j.euf.2018.03.008. Epub 2018 Mar 30.

PMID:
29609897
25.

Exact Time-Dependent Exchange-Correlation Potential in Electron Scattering Processes.

Suzuki Y, Lacombe L, Watanabe K, Maitra NT.

Phys Rev Lett. 2017 Dec 29;119(26):263401. doi: 10.1103/PhysRevLett.119.263401. Epub 2017 Dec 27.

PMID:
29328727
26.

Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review.

Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V.

Can Urol Assoc J. 2017 Dec;11(12):419-424. doi: 10.5489/cuaj.4471. Epub 2017 Nov 1. Review.

27.

Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study.

Allaire J, Léger C, Ben-Zvi T, Nguilé-Makao M, Fradet Y, Lacombe L, Fradet V.

Nutr Cancer. 2017 Nov-Dec;69(8):1196-1204. doi: 10.1080/01635581.2017.1367941. Epub 2017 Oct 30.

PMID:
29083243
28.

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.

Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y.

BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25.

29.

Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.

Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F.

Eur Urol Focus. 2017 Dec;3(6):639-642. doi: 10.1016/j.euf.2017.02.007. Epub 2017 Feb 23.

30.

Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.

Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A.

Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.

31.

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.

Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG.

Eur Urol. 2017 Nov;72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. Epub 2017 May 13.

PMID:
28511883
32.

Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7].

Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA.

Urol Oncol. 2017 Mar;35(3):124. doi: 10.1016/j.urolonc.2017.01.018. No abstract available.

PMID:
28215848
33.

Genomic hallmarks of localized, non-indolent prostate cancer.

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC.

Nature. 2017 Jan 19;541(7637):359-364. doi: 10.1038/nature20788. Epub 2017 Jan 9.

PMID:
28068672
34.

Quality indicators in the management of bladder cancer: A modified Delphi study.

Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W.

Urol Oncol. 2017 Jun;35(6):328-334. doi: 10.1016/j.urolonc.2016.12.003. Epub 2017 Jan 3.

PMID:
28065393
35.

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.

Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Têtu B, Lindberg J, Egevad L, Grönberg H, Ross-Adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC.

Eur Urol. 2017 Jul;72(1):22-31. doi: 10.1016/j.eururo.2016.10.013. Epub 2016 Nov 1.

PMID:
27815082
36.

A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks.

Pellerin C, McKercher G, Aprikian AG, Saad F, Lacombe L, Carmel M, Chevalier S.

Biopreserv Biobank. 2016 Oct;14(5):383-389. Epub 2016 Jun 21.

PMID:
27327090
37.

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R.

Cancer Immunol Res. 2016 Oct;4(10):881-892. Epub 2016 Sep 7.

38.

Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer.

Forbes CM, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lacombe L, Kawakami J, Drachenberg DE, Pautler SE, Jewett MMA, Saarela O, Liu Z, Tanguay S, Black PC.

Urol Oncol. 2016 Nov;34(11):486.e17-486.e23. doi: 10.1016/j.urolonc.2016.05.034. Epub 2016 Jul 14.

PMID:
27423824
39.

The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System.

Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA.

Urol Oncol. 2016 Nov;34(11):486.e1-486.e7. doi: 10.1016/j.urolonc.2016.05.025. Epub 2016 Jun 22. Erratum in: Urol Oncol. 2017 Mar;35(3):124.

PMID:
27344410
40.

Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes.

Nayak JG, Patel P, Saarela O, Liu Z, Kapoor A, Finelli A, Tanguay S, Rendon R, Moore R, Black PC, Lacombe L, Breau RH, Kawakami J, Drachenberg DE.

Urology. 2016 Aug;94:154-60. doi: 10.1016/j.urology.2016.03.029. Epub 2016 Mar 31.

PMID:
27041471
41.

Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients.

Gagné-Loranger M, Lacombe L, Pouliot F, Fradet V, Dagenais F.

Eur J Cardiothorac Surg. 2016 Aug;50(2):317-21. doi: 10.1093/ejcts/ezw023. Epub 2016 Mar 25.

PMID:
27016196
42.

CUA guidelines on the management of non-muscle invasive bladder cancer.

Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, So A, Lacombe L, Rendon R, Aprikian AG, Siemens DR, Izawa JI, Black P.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704. doi: 10.5489/cuaj.3320. Epub 2015 Oct 13. No abstract available.

43.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.

Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8.

44.

Canadian guidelines for the management of small renal masses (SRM).

Jewett MA, Rendon R, Lacombe L, Karakiewicz PI, Tanguay S, Kassouf W, Leveridge M, Cagiannos I, Kapoor A, Pautler S, Drachtenberg D, Moore R, Gleave M, Evans A, Haider M, Finelli A.

Can Urol Assoc J. 2015 May-Jun;9(5-6):160-3. doi: 10.5489/cuaj.2969. No abstract available.

45.

The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.

Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E.

Eur Urol. 2016 Apr;69(4):601-609. doi: 10.1016/j.eururo.2015.06.054. Epub 2015 Jul 26.

PMID:
26215610
46.

Surgical management of stage T1 renal tumours at Canadian academic centres.

Lavallée LT, Tanguay S, Jewett MA, Wood L, Kapoor A, Rendon RA, Moore RB, Lacombe L, Kawakami J, Pautler SE, Drachenberg DE, Black PC, Lattouf JB, Morash C, Cagiannos I, Liu Z, Breau RH.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):99-106. doi: 10.5489/cuaj.2598. Erratum in: Can Urol Assoc J. 2016 Aug;10 (7-8):E281.

47.

Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.

Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V.

Diagn Pathol. 2015 Jun 13;10:67. doi: 10.1186/s13000-015-0294-0.

48.

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.

Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F.

Cancer Imaging. 2015 Mar 3;15:2. doi: 10.1186/s40644-015-0038-0.

49.

CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Jung ME, Huang J, Wu L.

Cancer Res. 2015 Mar 15;75(6):950-62. doi: 10.1158/0008-5472.CAN-14-0992. Epub 2015 Mar 3.

50.

Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis.

Paquet ÉR, Hovington H, Brisson H, Lacombe C, Larue H, Têtu B, Lacombe L, Fradet Y, Lebel M.

Biomark Med. 2015;9(3):187-97. doi: 10.2217/bmm.14.115.

PMID:
25731206

Supplemental Content

Loading ...
Support Center